Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial.

[1]  H. Kolb,et al.  Chemokines and Incident Coronary Heart Disease: Results From the MONICA/KORA Augsburg Case-Cohort Study, 1984–2002 , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[2]  F. Breedveld,et al.  A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[3]  L. See,et al.  RANTES and monocyte chemoattractant protein 1 as sensitive markers of disease activity in patients with juvenile rheumatoid arthritis: a six-year longitudinal study. , 2006, Arthritis and rheumatism.

[4]  Amy Shui,et al.  Clinical Relevance of C-Reactive Protein During Follow-Up of Patients With Acute Coronary Syndromes in the Aggrastat-to-Zocor Trial , 2006, Circulation.

[5]  Lu Tian,et al.  Narrative Review: Assessment of C-Reactive Protein in Risk Prediction for Cardiovascular Disease , 2006, Annals of Internal Medicine.

[6]  R. Califf,et al.  Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. , 2005, JAMA.

[7]  E. Boerwinkle,et al.  Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: Atherosclerosis Risk in Communities study. , 2005, Atherosclerosis.

[8]  J. Hirschhorn,et al.  CCL2 Polymorphisms Are Associated With Serum Monocyte Chemoattractant Protein-1 Levels and Myocardial Infarction in the Framingham Heart Study , 2005, Circulation.

[9]  A. Khera,et al.  Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis. , 2004, Journal of the American College of Cardiology.

[10]  P. Kovanen,et al.  Prognostic usefulness of plasma monocyte/macrophage and T-lymphocyte activation markers in patients with acute coronary syndromes. , 2004, The American journal of cardiology.

[11]  M. Pfeffer,et al.  Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. , 2004, JAMA.

[12]  V. Hasselblad,et al.  Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. , 2004, JAMA.

[13]  Shuiping Zhao,et al.  Atorvastatin reduces plasma MCP-1 in patients with acute coronary syndrome. , 2003, Clinica chimica acta; international journal of clinical chemistry.

[14]  K. Arnesen,et al.  Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease. , 2003, Journal of the American College of Cardiology.

[15]  E. Antman,et al.  Association Between Plasma Levels of Monocyte Chemoattractant Protein-1 and Long-Term Clinical Outcomes in Patients With Acute Coronary Syndromes , 2003, Circulation.

[16]  Gary L Myers,et al.  Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. , 2003, Circulation.

[17]  Y. Kaneda,et al.  Local Overexpression of Monocyte Chemoattractant Protein‐1 at Vessel Wall Induces Infiltration of Macrophages and Formation of Atherosclerotic Lesion: Synergism With Hypercholesterolemia , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[18]  W. Daniel,et al.  Upregulation of CD40 and CD40 Ligand (CD154) in Patients With Moderate Hypercholesterolemia , 2001, Circulation.

[19]  M. Sabatine,et al.  The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. , 2001, The New England journal of medicine.

[20]  R. Califf,et al.  The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. , 2001, American heart journal.

[21]  A. Aljada,et al.  Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. , 2001, The Journal of clinical endocrinology and metabolism.

[22]  R. Berge,et al.  Interaction between chemokines and oxidative stress: possible pathogenic role in acute coronary syndromes. , 2001, Journal of the American College of Cardiology.

[23]  J. Kelley,et al.  Human endothelium as a source of multifunctional cytokines: molecular regulation and possible role in human disease. , 1999, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[24]  I. Charo,et al.  Decreased lesion formation in CCR2−/− mice reveals a role for chemokines in the initiation of atherosclerosis , 1998, Nature.

[25]  P. Libby,et al.  Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. , 1998, Molecular cell.

[26]  E. Antman,et al.  C-Reactive Protein Is a Potent Predictor of Mortality Independently of and in Combination With Troponin T in Acute Coronary Syndromes: A TIMI 11A Substudy , 1998 .

[27]  B. Rollins,et al.  Tissue Factor Is Induced by Monocyte Chemoattractant Protein-1 in Human Aortic Smooth Muscle and THP-1 Cells* , 1997, The Journal of Biological Chemistry.

[28]  S. Coughlin,et al.  Monocyte chemoattractant protein-1 in human atheromatous plaques. , 1991, The Journal of clinical investigation.